Literature DB >> 17379484

The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.

Wendy Ooteman1, Maarten W J Koeter, Roel Verheul, Gerard M Schippers, Wim van den Brink.   

Abstract

INTRODUCTION: Acamprosate and naltrexone have been shown to be effective in relapse prevention of alcoholism. It is hypothesized that naltrexone exerts its effects primarily on cue-induced craving and neuroendocrine cue reactivity, whereas acamprosate exerts its effect primarily on autonomic nervous system reactions to alcohol-related cues. EXPERIMENTAL PROCEDURES: In a randomized double-blind experiment, 131 abstinent alcoholics received either acamprosate (n=56), naltrexone (n=52) or placebo (n=23) for three weeks and participated in two cue-exposure sessions: the first the day before and the second at the last day of medication.
RESULTS: Consistent with the hypotheses, naltrexone reduced craving more than acamprosate, and acamprosate reduced heart rate more than naltrexone. No medication effect was found on cue-induced cortisol. DISCUSSION: The findings provide some evidence for differential effects of naltrexone and acamprosate: naltrexone may exert its effect, at least partly, by the reduction of cue-induced craving, whereas acamprosate may exert its effect, at least partly, by the reduction of autonomic nervous system reactions to alcohol-related cues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379484     DOI: 10.1016/j.euroneuro.2007.02.012

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  21 in total

1.  Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.

Authors:  John C Umhau; Melanie L Schwandt; Julie Usala; Christopher Geyer; Erick Singley; David T George; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

2.  Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Authors:  Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2020-05-25       Impact factor: 3.455

3.  Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.

Authors:  Corey R Roos; Karl Mann; Katie Witkiewitz
Journal:  Addict Biol       Date:  2016-08-02       Impact factor: 4.280

4.  Opioid receptors in the basolateral amygdala but not dorsal hippocampus mediate context-induced alcohol seeking.

Authors:  Peter W Marinelli; Douglas Funk; Walter Juzytsch; A D Lê
Journal:  Behav Brain Res       Date:  2010-03-07       Impact factor: 3.332

Review 5.  New steps for treating alcohol use disorder.

Authors:  Erin J Campbell; Andrew J Lawrence; Christina J Perry
Journal:  Psychopharmacology (Berl)       Date:  2018-03-25       Impact factor: 4.530

Review 6.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

7.  Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Authors:  Maria A Sullivan; Adam Bisaga; John J Mariani; Andrew Glass; Frances R Levin; Sandra D Comer; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2013-07-01       Impact factor: 4.492

8.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

9.  A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.

Authors:  Sung-Gon Kim; Cheol-Min Kim; Sam-Wook Choi; Young-Myo Jae; Hae-Gook Lee; Bong-Ki Son; Jeong-Gee Kim; Young-Sung Choi; Han-Oh Kim; Seong-Yeon Kim; David W Oslin
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

Review 10.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.